Webinar

Microplate
#Automation #Automation / robotics #Drug discovery #Lab technology #Webinar

Register to explore the orchestrated lab: Moving beyond siloed automation

Many laboratories have invested in automation, yet workflows often remain fragmented, with disconnected instruments, data, and processes creating inefficiencies and limiting scalability. As scientific workflows grow more complex, automation alone is no longer enough. Leading labs are now embracing orchestration, the coordination of instruments, robotics, software, data, and people across… Read More

#News

KRAS
#Champions Oncology #Drug discovery #KRAS #Oncology #Patient-derived tumour models #Tumour models #Webinar

Webinar explores resistance to Pan-RAS(ON) inhibition

KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More

#News

#Drug discovery #Fragment-based drug discovery #Webinar

Webinar: Learn how to accelerate the early stages of drug discovery

Fragment-based drug discovery (FBDD) offers an efficient route to explore chemical space, but critical bottlenecks remain. Commercial fragment libraries are either too large to screen routinely with biophysical methods or too small to capture sufficient chemical diversity for challenging targets. Moreover, fragment expansions into focused compound collections lacks streamlined, integrated… Read More

#News

#Artificial intelligence (AI) #High throughput screening #Transcriptomics #Webinar

Webinar: Building the data layer for AI drug discovery

AI-driven drug discovery depends on large-scale, information-rich biological datasets that capture how compounds perturb cellular systems across diverse conditions. Building these datasets requires scalable approaches that can combine phenotypic and molecular readouts in high-throughput screening workflows. In this webinar, hosted by DDW, Daniel Alpern, Chief Scientific Officer at… Read More

#News

Lab automation
#Automation #Automation / robotics #Drug discovery #Lab technology #Webinar

Learn more about lab workflow scheduling and orchestration

Many laboratories have invested in automation, yet workflows often remain fragmented, with disconnected instruments, data, and processes creating inefficiencies and limiting scalability. As scientific workflows grow more complex, automation alone is no longer enough. Leading labs are now embracing orchestration, the coordination of instruments, robotics, software, data, and people across… Read More

#News

#Biosafety testing #Drug discovery #Next generation sequencing #Webinar

Watch now: Discover an NGS-based AVA assay with enhanced sensitivity and specificity

Biopharmaceutical manufacturers are under increasing pressure to deliver safe, reliable products at speed – yet adventitious viral agent (AVA) testing remains one of the most significant bottlenecks in the quality control process. In this on-demand webinar, ViruSure, a global leader in pathogen safety testing, shares how it… Read More

Webinar date:
Supported by Oxford Nanopore Technologies and ViruSure
#News

Test for KRAS mutation
#Champions Oncology #Drug discovery #KRAS #Oncology #Patient-derived tumour models #Tumour models #Webinar

Lessons from 50+ patient-derived KRAS-mutant tumour models

KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More

#News

#Artificial intelligence (AI) #High throughput screening #Transcriptomics #Webinar

Building the data layer for Al drug discovery: Cell painting and DRUG-seq in large-scale compound screens

AI-driven drug discovery depends on large-scale, information-rich biological datasets that capture how compounds perturb cellular systems across diverse conditions. Building these datasets requires scalable approaches that can combine phenotypic and molecular readouts in high-throughput screening workflows. In this webinar, hosted by DDW, Daniel Alpern, Chief Scientific Officer at Alithea Genomics,… Read More

Webinar date:
Supported by Alithea Genomics and Revvity
#Webinars

#Drug discovery #Fragment-based drug discovery #Webinar

Webinar: Learn how to accelerate the early stages of drug discovery

Fragment-based drug discovery (FBDD) offers an efficient route to explore chemical space, but critical bottlenecks remain. Commercial fragment libraries are either too large to screen routinely with biophysical methods or too small to capture sufficient chemical diversity for challenging targets. Moreover, fragment expansions into focused compound collections lacks streamlined, integrated… Read More

#News

Automation
#Automation #Automation / robotics #Drug discovery #Lab technology #Webinar

Webinar: Moving beyond siloed automation with an orchestrated lab

Many laboratories have invested in automation, yet workflows often remain fragmented, with disconnected instruments, data, and processes creating inefficiencies and limiting scalability. As scientific workflows grow more complex, automation alone is no longer enough. Leading labs are now embracing orchestration, the coordination of instruments, robotics, software, data, and people across… Read More

#News

#Biosafety testing #Drug discovery #Next generation sequencing #Webinar

Webinar: Consolidate multiple assays into a single, comprehensive AVA test

Biopharmaceutical manufacturers are under increasing pressure to deliver safe, reliable products at speed – yet adventitious viral agent (AVA) testing remains one of the most significant bottlenecks in the quality control process. In this on-demand webinar, ViruSure, a global leader in pathogen safety testing, shares how it… Read More

Webinar date:
Supported by Oxford Nanopore Technologies and ViruSure
#News

#Champions Oncology #Drug discovery #KRAS #Oncology #Patient-derived tumour models #Tumour models #Webinar

Decoding Pan-RAS(ON) inhibitor activity across KRAS models: Webinar

KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More

#News

#Automation #Automation / robotics #Drug discovery #Lab technology #Webinar

Webinar – The orchestrated lab: Moving beyond siloed automation

Many laboratories have invested in automation, yet workflows often remain fragmented, with disconnected instruments, data, and processes creating inefficiencies and limiting scalability. As scientific workflows grow more complex, automation alone is no longer enough. Leading labs are now embracing orchestration, the coordination of instruments, robotics, software, data, and people across… Read More

#News

#Drug discovery #Fragment-based drug discovery #Webinar

Webinar: Overcome critical bottlenecks in fragment-based drug discovery

Fragment-based drug discovery (FBDD) offers an efficient route to explore chemical space, but critical bottlenecks remain. Commercial fragment libraries are either too large to screen routinely with biophysical methods or too small to capture sufficient chemical diversity for challenging targets. Moreover, fragment expansions into focused compound collections lacks streamlined, integrated… Read More

#News

Antibody discovery concept
#Artificial intelligence (AI) #Biologics #Drug discovery #Therapeutic Antibodies #Webinar

Webinar: Modernise and scale your antibody discovery programmes

Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programs on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar, hosted by… Read More

Webinar date:
Supported by Benchling
#News

Biosafety testing
#Biosafety testing #Drug discovery #Next generation sequencing #Webinar

Webinar: How can a single, comprehensive test enable broader viral detection?

Biopharmaceutical manufacturers are under increasing pressure to deliver safe, reliable products at speed – yet adventitious viral agent (AVA) testing remains one of the most significant bottlenecks in the quality control process. In this on-demand webinar, ViruSure, a global leader in pathogen safety testing, shares how it… Read More

Webinar date:
Supported by Oxford Nanopore Technologies and ViruSure
#News